No significant cognitive impairment operationalized as either an intelligence quotient (IQ) < 70 for children with SJMB12 baseline testing or based on clinician judgment in the case of missing baseline IQ
No major sensory or motor impairment that would preclude valid cognitive testing (e.g., unresolved posterior fossa syndrome, blindness, poorly controlled seizures/photosensitive epilepsy, psychosis) or a major psychological condition that would preclude completion of the intervention (e.g., significant oppositionality, autism spectrum disorder, severe anxiety or depressive symptoms)
Significant cognitive impairment or documented psychologic impairment
Conditions that may increase the risk of the diet or significantly reduce compliance (i.e. cognitive impairment, frank dementia, etc)
Performance status >= 70% (Karnofsky); patients > 50 years should have adequate cognitive function; any concerns regarding cognitive function should be addressed by a geriatrician/neurologist;
Prior cognitive-behavioral therapy
Performance status >=70% (Karnofsky); patients > 50 years should have adequate cognitive function; any concerns regarding cognitive function should be addressed by a geriatrician/neurologist
Baseline Montreal Cognitive Assessment (MOCA) score of 22 or lower
Cognitive or mental health impairment that inhibits group treatment
Cognitive impairment that precludes a patient from acting as his or her own agent to provide informed consent
Considered by the investigator to be an unsuitable or unstable candidate (e.g., due to cognitive impairment)
Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc).
Cognitive impairment such as to preclude informed consent
Baseline Montreal Cognitive Assessment (MOCA) score of 22 or lower
Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc.)
Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc).
Cognitive impairment
All patients must be able to adequately read, write and speak to participate in the cognitive and quality of life assessments; however mild to moderate deficits in these functions due to tumor are allowed
Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc.).
Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc).
Cognitive impairment, history of medical or psychiatric disease, other uncontrolled intercurrent illness, active substance abuse, or social circumstances, which in the view of the principal investigator (PI), would preclude safe treatment or the ability to give informed consent
In the opinion of the treating investigator, patients must have adequate cognitive abilities to complete the neurocognitive components of the study.
Patient with cognitive impairment
Baseline Montreal Cognitive Assessment (MOCA) score of 22 or lower.
Any condition, psychiatric or otherwise, that would preclude informed consent, consistent follow-up or compliance with any aspect of the study (e.g., untreated schizophrenia or other significant cognitive impairment, etc.).
Cognitive impairment sufficient to render the patient incapable of giving informed consent
Patients with cognitive impairment or likely to develop cognitive impairment while on study
Patients must have the cognitive ability to participate in the study
Global cognitive impairment based on education-adjusted scores (details below) on the Telephone Interview for Cognitive Status-modified
The presence of a physical or cognitive impairment that would prevent a person from engaging in survey research (such as blindness, deafness, or dementia)
PATIENT: They have cognitive or psychiatric conditions as determined by the treating oncologist to prohibit study consent or participation
CAREGIVER: They have cognitive or psychiatric conditions as determined by the treating oncologist to prohibit study consent or participation
Prior history of neurologic or psychiatric disease believed to impact cognitive function
Patients scoring >= 11 on the Blessed Orientation-Memory-Concentration Test (BOMC) (implying cognitive impairment) will be excluded since their ability to reliably complete the questionnaire will be in doubt
Overt cognitive difficulty demonstrated by not being clearly oriented to person or place or time
Significant cognitive impairment or documented psychologic impairment
Severe cognitive or hearing impairment that is documented in the medical record (one that would make it difficult to comprehend and remember the material covered during study phone sessions)
Unable to provide meaningful consent (e.g., severe cognitive impairment)
Presence of cognitive impairment disorder (i.e. delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection, as detected during the ICCAN intake process
In the judgment of the consenting professional, clinician or principal investigator (PI) and/or as per medical record, severe psychopathology or cognitive impairment likely to interfere with the participation or completion of the protocol or ability to provide meaningful information.
Women with cognitive impairment that precludes informed consent and those unable to provide consent in English
Cognitive or psychiatric conditions prohibiting study consent or participation
If visual, hearing, or cognitive impairment will interfere with intervention
Patients must have subjective complaints of cognitive deficits
They have cognitive or psychiatric conditions as determined by the treating oncologist to prohibit study consent or participation
No history of cognitive disorder
Are of limited decision making capacity, including those who score 16 or less on the Montreal Cognitive Assessment (MoCA) assessment
Patient scores >= 7 on the Mini-Mental Adjustment to Cancer cognitive avoidance subscale
Patient makes 3 or more errors on a validated 6-item cognitive screener or exhibits significant psychiatric or cognitive impairment (e.g., dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation
FCG exhibits significant psychiatric or cognitive impairment (e.g., dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation
History of neurological disease (e.g., Parkinson’s Disease, dementia, mild cognitive impairment)
PATIENT ONLY: Cognitive deficits that would impede the completion of self-report instruments as deemed by the clinical team
Patients with cognitive deficits
Significant cognitive impairment
Significant cognitive impairment as determined by either an intelligence quotient (IQ) of =< 70 or by clinician judgment
Major sensory or motor impairment that would preclude valid cognitive testing
Inability of the patient to provide informed consent (i.e. dementia, cognitive impairment, non-English speakers)
Medical or other issue prohibiting computer use, reading or ability to comply with all study procedures or unable to communicate via phone (e.g., significant vision, hearing or cognitive impairment, major illness, hospitalization)
PATIENTS: Cognitive deficits that would impede the completion of self-report instruments as deemed by the clinical team.
The child has a significant cognitive impairment that might hinder participation (determination made in consultation with attending physician, oncologist, and parents)
Do not have cognitive or visual impairments that would preclude use of the app
Cognitive or hearing impairment
Significant psychiatric, cognitive or other comorbid disease which the treating clinician believes prohibits informed consent or participation in the study
Significant psychiatric, cognitive or other comorbid disease which the treating clinician believes prohibits informed consent or participation in the study
Cognitive impairment evident patients will be evaluated with Folstein Mini-Mental Status Examination and excluded with a score less than 25
Severe cognitive dysfunction impairing ability to provide informed consent or consume study drug
Cognitive impairment or inability to consent to treatment, as determined by the patient's oncologist
PHASE 1: PATIENT EXCLUSION CRITERIA: Physician- or self-reported cognitive delay or impairment that would prevent self-management of healthcare
PHASE 1: PARENT EXCLUSION CRITERIA: Patient has physician- or caregiver-reported cognitive delay or impairment that would prevent self-management of healthcare
PHASE 2: PATIENT EXCLUSION CRITERIA: Physician- or self-reported cognitive delay or impairment that would prevent self-management of healthcare
PHASE 3A/3B: PATIENT EXCLUSION CRITERIA: Physician- or self-reported cognitive delay or impairment that would prevent self-management of healthcare
Known medical history of significant psychiatric or cognitive impairment
DCG: Cognitive impairment
Cognitive impairment
And/or in the rare instance of the presence of a comorbidity that does not fall into any of the above mentioned exclusion criteria, but that is clinically determined to significantly interfere with the patient’s ability to participate in the study (e.g., cognitive impairment)
Patients with significant cognitive impairment or documented psychologic impairment
Doctor of medicine (MD) confirmed cognitive impairment
Cognitive impairment documented in the medical record
Unable to provide meaningful consent (e.g., women with severe cognitive impairment such that the descriptions of the research are not clearly understood will be excluded)
Medical record documentation of cognitive impairment that would preclude the ability to provide informed consent
Clinically evident cognitive and/or behavioral impairment that in the opinion of the study investigator would impair the ability of the patient to adhere to the study procedures, specifically completing home activity monitoring
Cognitive impairment as indicated by a baseline Folstein Mini-Mental Status Examination of < 25
Can provide informed consent (e.g., no cognitive impairment)
SUBJECT: Significant cognitive, behavioral, or emotional impairments as judged by an investigator that would prevent the child from understanding or completing the intervention or assessment measures.
Moderate or worse cognitive impairment as indicated by a score of 3 or less on the Callahan six-item cognitive screening tool
Clear cognitive sequelae from the head injury and cognitive rehabilitation following the injury
In the investigator's judgment, participants must have satisfactory cognitive function to provide valid informed consent and participate in Geriatric Specific Psychoeducational Intervention; the Blessed Orientation-Memory-Concentration test (BOMC) will be used as a cognitive screening tool; patients must have a BOMC score less than or equal to 11
Patients who do not have a smart phone, have a serious mental illness or cognitive impairment, e.g., psychosis or dementia, do not speak English or cannot fill their oral oncolytic prescription at the\r\nUniversity of Michigan Comprehensive Cancer Center pharmacy will be unable to participate in this study
Cognitive or psychiatric disorder that would interfere with ability to provide informed consent or answer survey questions reliably\r\n* Any of these Diagnostic and Statistical Manual-5 (DSM-5) cognitive and psychiatric disorders would make someone ineligible: bipolar; delusional; dissociative; intellectual developmental; neurocognitive; psychotic; schizophreniform, schizophrenia, and schizoaffective
PATIENTS ONLY: Cognitive deficits that would impede the completion of self-report instruments as deemed by the clinical team
Patients with opioid induced neurotoxicity (OIN) as the primary reason for OR as they may manifest symptoms of cognitive impairment
Major psychiatric diagnosis that impairs cognitive functioning or is not controlled at the time of the approach.
Patients with cognitive dysfunction
Self-report of a discrepancy between present and optimal level of cognitive, emotional, and/or physical functioning
PHASE I AIM 1: Clinical evidence of cognitive or psychological impairment
PHASE I AIM 3.1: Clinical evidence of cognitive or psychological impairment
PHASE I AIM 3.2: Clinical evidence of cognitive or psychological impairment
PHASE II AIM 2: Clinical evidence of cognitive or psychological impairment
No evidence of dementia (Mini Mental State Examination [MMSE] >= 23) but some evidence of cognitive impairment (each subject will be required to answer in the affirmative: ‘do you have problems with memory and attention since having chemotherapy, and do you believe chemotherapy contributed to the problems?’)
Existing history of severe cognitive impairment in the child as reported by the parents or documented in the child's City of Hope medical records
Diagnosed cognitive impairment
Severe cognitive impairment
Previously identified cognitive impairment, which in the judgment of the principal or associate investigators would compromise the donor’s ability to understand the educational materials or the board game rules and procedures, and is likely to interfere with the study procedures or results
EXCLUSION CRITERIA FOR CAREGIVERS: caregivers unable to understand the consent form due to cognitive, health, or sensory impairment will be excluded
Cognitive impairment (part II only)
Severe cognitive, visual, or hearing impairment that would preclude DA viewing
Cognitive impairment as assessed by the 6-item Mini-Mental Status Exam
Cognitive impairment or mental illness that would impair ability to provide consent or participate in the program
Patients with known cognitive impairments
FACT-Cog score less than 59 on the Perceived Cognitive Impairment subscale
Subjective complaint of cognitive concerns at time of enrollment
Patients with a history of stroke or other pre-existing neurological condition that may contribute to cognitive dysfunction.
Hearing level and cognitive ability to follow test directions
Neurological or cognitive impairment
Able to undergo informed consent procedures and 3 hours of testing, plus 8 1-hour cognitive rehabilitation sessions with breaks
They have cognitive or psychiatric conditions as determined by the treating oncologist that prohibits study consent or participation
Normal cognitive status as determined by the interviewer based on the ability to understand the nature of the study and consent process.
Overt cognitive dysfunction or psychiatric disturbance such as suicidal ideation or severe mental illness, as observed or judged by the researcher, referring source, or other qualified observer
Currently on stimulants or other medications intended to treat cognitive impairment
Report cognitive impairment since starting chemotherapy as assessed by four questions from the Functional Assessment of Cancer Therapy Cognitive Scale (FACT-Cog)
Major psychiatric illness or cognitive impairment that in the judgment of the investigator would preclude study participation
Patient makes 3 or more errors on a validated 6-item cognitive screener or exhibits significant psychiatric or cognitive impairment (dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation
Caregiver exhibits significant psychiatric or cognitive impairment (dementia/delirium, retardation, active psychosis) that in the judgment of the investigators would preclude providing informed consent and study participation
Significant psychiatric or cognitive disturbance sufficient, in the investigator's judgment, to preclude providing informed consent or participating in the groups (i.e., acute psychiatric symptoms which require individual treatment)
Presence of untreated psychiatric disturbance (i.e. acute psychiatric symptoms which require individual treatment) and/or cognitive impairment disorder (e.g., delirium or dementia) verified by medical record sufficient to preclude completion of the assessment measures, interview or informed consent
Regularly used cognitive behavioral therapy in the last 6 weeks for sleep disturbance
Regularly used cognitive behavioral therapy in the last 6 weeks
Cognitive impairment (>= 5 on the Short Portable Mental Status Questionnaire [SPMSQ])
Intact cognitive status
Do not have cognitive or psychiatric conditions prohibiting participation
Previous participation in cognitive training program
Cognitive impairment that prevents participant from answering questions in standardized assessments
Cognitive deficits
Cognitive, language or hearing problems
No cognitive impairment
Individuals that have limited cognitive function/developmental disabilities
Uncontrolled congestive heart failure third-degree atrio-ventricular heart block, active pericarditis or myocarditis, recent embolism, thrombophlebitis, deep vein thrombosis, resting ST displacement (> 3 mm), uncontrolled diabetes, uncontrolled pain, cognitive impairment, history of falls due to balance impairment or lost of consciousness
Any impairment (e.g., hearing, visual, cognitive) that interferes with the ability to complete all measures independently
Presence of a serious psychiatric or cognitive impairment likely to preclude meaningful informed consent and adherence to the protocol per the consenting professional's judgement
Excluded from this study will be prisoners, pregnant women, patients with a contraindication for additional lung biopsies, and patients who cannot give informed consent (language barrier, cognitive impairment, etc.)
Dementia or other severe cognitive impairment causing inability to understand or consent to the procedure and study
The patient must report persistent cognitive problems following the initiation of chemotherapy, defined as impairment being one or more standard deviations above normative data on our two scales of subjective cognitive dysfunction; this is defined as a total score of 45 or higher on the Cognitive Failure Questionnaire, and a T-score of 60 or higher on the Frontal System Behavioral Scale Questionnaire
Current use of cholinesterase inhibitors, other cognitive enhancers, antipsychotics, antidepressants, or anticonvulsant medications
Patients incapable of giving informed written consent, due to mental disability, altered mental status,\r\nconfusion, cognitive impairment, or psychiatric disorders\r\n* Patients scoring 14.5 or lower on the University of California, San Diego Brief Assessment of Capacity to Consent (UBACC) questionnaire will not be allowed on study
Patients incapable of giving informed written consent, for the following reasons:\r\n* Inability to adhere to the experimental protocols for any reason\r\n* Inability to communicate with the research team\r\n* Limited ability to give informed consent due to mental disability, altered mental status, confusion, cognitive impairment, or psychiatric disorders\r\n** Patients scoring 14.5 or lower on the University of California at San Diego (UCSD) Brief Assessment of Consent Capacity (UBACC) Capacity to Consent Questionnaire will be excluded\r\n* Prisoners or other individuals deemed to be susceptible to coercion
Report any level of cognitive difficulty to the question, “Are you currently experiencing any cognitive problems (such as in your memory, attention, concentration, multi-tasking) since your cancer diagnosis?” at chemotherapy cycle 4 or after; participant must answer YES to this question\r\n* NOTE: If a participant answers NO, you may re-approach them at a subsequent cycle
History of cognitive impairment.
PHASE I: Women with capacity to participate but mild cognitive impairment (MCI)
Overt cognitive difficulty demonstrated by not being clearly oriented to time or person or place (Arms 1-4)
Mothers need to be free of serious mental illness (e.g., cognitive and psychotic disorders) or developmental disability that would limit participation or preclude informed consent
Significant psychiatric or cognitive disturbance sufficient, in the consenting professional's or investigator's judgment, to preclude providing informed consent or participating in the interventions (i.e., acute psychiatric symptoms which require individual treatment)
Patients who have clinical evidence of cognitive impairment as determined by the research staff
Altered cognitive status as determined by the interviewer based on the ability to understand the nature of the study and consent process
Cognitive impairment
